| Field | Specification |
|---|---|
| Target | |
| Alternative names | ADP-ribosylation factor 6;ARF6; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human ARF6 recombinant protein (Position: G2-S175). Human ARF6 shares 100% amino acid (aa) sequence identity with both mouse and rat ARF6. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects ADP-ribosylation factor 6 (gene ARF6) in human, mouse and rat samples and is validated for flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 20.1 kDa, and the supplier reports an observed band at about 20 kDa.
ADP-ribosylation factor 6 (ARF6) is a small GTPase that acts at the plasma membrane and endosomes. It regulates endocytic recycling, phosphoinositide signaling and actin remodeling, and it is studied in cell migration, cell spreading, cytokinesis and tumor cell invasion.
| Target | ADP-ribosylation factor 6 (gene ARF6; UniProt P62330, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 20.1 kDa |
| Observed MW | 20 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Human, Rat) |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): rat kidney tissue, mouse kidney tissue, MCF-7 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human melanoma tissue, rat cardiac muscle tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): A431 cells.
Samples with a confirmed signal (flow cytometry): SiHa cells.
Immunogen
Recombinant human ARF6 fragment (Gly2–Ser175), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 100%.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places ADP-ribosylation factor 6 in the cytoplasm, cell membrane, endosome membrane and recycling endosome membrane. Tissue expression noted by UniProt (human): Ubiquitous, with higher levels in heart, substantia nigra, and kidney. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
